<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591717</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-COVID-19-hAd5-Vaccine</org_study_id>
    <nct_id>NCT04591717</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers</brief_title>
  <official_title>Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is&#xD;
      designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD&#xD;
      vaccine and select a dose for future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">November 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of MAAEs and SAEs</measure>
    <time_frame>1 week</time_frame>
    <description>Incidence of MAAEs and SAEs through 1 week post final vaccine administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of solicited local reactogenicity AEs</measure>
    <time_frame>1 week</time_frame>
    <description>Incidence and severity of solicited local reactogenicity AEs through 1 week post final vaccine administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of solicited systemic reactogenicity AEs</measure>
    <time_frame>1 week</time_frame>
    <description>Incidence and severity of solicited systemic reactogenicity AEs through 1 week post final vaccine administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of unsolicited AEs</measure>
    <time_frame>1 week</time_frame>
    <description>Incidence and severity of unsolicited AEs through 1 week post final vaccine administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of MAAEs and SAEs</measure>
    <time_frame>30 days to 6 months</time_frame>
    <description>Incidence of MAAEs and SAEs through 30 days and 6 months post final vaccine administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of unsolicited AEs</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence and severity of unsolicited AEs through 30 days post final vaccine administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal changes of laboratory safety examinations</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of abnormal changes of laboratory safety examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Fever</measure>
    <time_frame>30 days</time_frame>
    <description>Changes in vital signs from Grades 1-4:&#xD;
- Fever - measured in (°C) or (°F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Tachycardia</measure>
    <time_frame>30 Days</time_frame>
    <description>Changes in vital signs from Grades 1-4:&#xD;
- Tachycardia - measured in beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Bradycardia</measure>
    <time_frame>30 Days</time_frame>
    <description>Changes in vital signs from Grades 1-4:&#xD;
- Bradycardia - measured in how many beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Hypertension</measure>
    <time_frame>30 Days</time_frame>
    <description>Changes in vital signs from Grades 1-4:&#xD;
- Hypertension (systolic/diastolic) - measured in mm Hg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Hypotension</measure>
    <time_frame>30 Days</time_frame>
    <description>Changes in vital signs from Grades 1-4:&#xD;
- Hypotension (systolic) - measured in mm Hg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Respiratory Rate</measure>
    <time_frame>30 Days</time_frame>
    <description>Changes in vital signs from Grades 1-4:&#xD;
- Respiratory Rate - measured in how many breaths per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFR in IgG titer</measure>
    <time_frame>Day 387</time_frame>
    <description>GMFR in IgG titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus</measure>
    <time_frame>Day 387</time_frame>
    <description>GMT of S-specific, RBD-specific, and N-specific antibodies against 2019 novel coronavirus tested by ELISA in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who seroconverted</measure>
    <time_frame>Day 387</time_frame>
    <description>Percentage of subjects who seroconverted (as defined as 4-fold change in antibody titer relative to baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFR in neutralizing antibody</measure>
    <time_frame>Day 387</time_frame>
    <description>GMFR in neutralizing antibody</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT</measure>
    <time_frame>Day 387</time_frame>
    <description>GMT of neutralizing antibody</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate of neutralizing antibody</measure>
    <time_frame>Day 387</time_frame>
    <description>Seroconversion rate of neutralizing antibody (as defined as 4-fold change in antibody titer relative to baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein</measure>
    <time_frame>Day 387</time_frame>
    <description>CD8+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein measured by ELISPOT assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein</measure>
    <time_frame>Day 387</time_frame>
    <description>CD4+ T-Cell activity against SARS-CoV-2 S protein, RBD, and N protein measured by standard immune assay</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 0.5 mL of hAd5-S-Fusion+N-ETSD SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of hAd5-S-Fusion+N-ETSD SC (5 × 1010 VP/dose) on days 1 and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 1011 VP/dose) on days 1 and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 1011 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 1010 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 1010 VP/dose) on day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 1011 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 1010 VP/dose) on day 1; 1.0 mL of hAd5-S-Fusion+N-ETSD sublingually (1 × 1011 VP/dose) on day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 1011 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 1010 VP/dose) on day 1; No vaccine on day 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hAd5-S-Fusion+N-ETSD vaccine</intervention_name>
    <description>The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.</description>
    <arm_group_label>Cohort 1: 0.5 mL of hAd5-S-Fusion+N-ETSD SC</arm_group_label>
    <arm_group_label>Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC</arm_group_label>
    <arm_group_label>Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually</arm_group_label>
    <arm_group_label>Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually</arm_group_label>
    <arm_group_label>Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults, age 18 - 55 years, inclusive, at time of enrollment.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          3. Agrees to the collection of biospecimens (eg, nasopharyngeal [NP] swabs) and venous&#xD;
             blood per protocol.&#xD;
&#xD;
          4. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
          5. Temperature &lt; 38°C.&#xD;
&#xD;
          6. Negative for SARS-CoV-2 (qPCR or LAMP test) and no known previous COVID-19 exposure or&#xD;
             disease.&#xD;
&#xD;
          7. Agreement to practice effective contraception for female subjects of childbearing&#xD;
&#xD;
        potential and non-sterile males. Female subjects of childbearing potential must agree to&#xD;
        use effective contraception while on study until at least 1 month after the last dose of&#xD;
        vaccine. Non-sterile male subjects must agree to use a condom while on study until at least&#xD;
        1 month after the last dose of vaccine. Effective contraception includes surgical&#xD;
        sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom,&#xD;
        diaphragm) used with spermicide, intrauterine devices (IUDs), oral contraceptives, and&#xD;
        abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to any component of the investigational vaccine, or a more severe allergic&#xD;
             reaction and history of allergies in the past.&#xD;
&#xD;
          2. Pregnant and nursing women. A negative serum or urine pregnancy test during screening&#xD;
             and on the day of and prior to each dose must be documented before the vaccine is&#xD;
             administered to a female subject of childbearing potential.&#xD;
&#xD;
          3. Live in a nursing home or long-term care facility.&#xD;
&#xD;
          4. Chronic lung disease including chronic obstructive pulmonary disease (COPD) or&#xD;
             moderate to severe asthma.&#xD;
&#xD;
          5. Pulmonary fibrosis.&#xD;
&#xD;
          6. Active smoker.&#xD;
&#xD;
          7. Bone marrow or organ transplantation.&#xD;
&#xD;
          8. Obesity (defined as body mass index [BMI] of 30 kg/m2 or higher).&#xD;
&#xD;
          9. Diabetes.&#xD;
&#xD;
         10. Chronic kidney disease.&#xD;
&#xD;
         11. Liver disease.&#xD;
&#xD;
         12. Sickle cell disease.&#xD;
&#xD;
         13. Thalassemia.&#xD;
&#xD;
         14. Doctors, nurses, first responders, and other healthcare workers working in direct&#xD;
             contact with COVID-19 patients.&#xD;
&#xD;
         15. Any disease associated with acute fever, or any infection.&#xD;
&#xD;
         16. Self-reported history of severe acute respiratory syndrome (SARS).&#xD;
&#xD;
         17. History of hepatitis B or hepatitis C.&#xD;
&#xD;
         18. HIV or other acquired or hereditary immunodeficiency.&#xD;
&#xD;
         19. Serious cardiovascular diseases, such as heart failure, coronary artery disease,&#xD;
             cardiomyopathies, arrhythmia, conduction block, myocardial infarction, pulmonary&#xD;
             hypertension, severe hypertension without controllable drugs, etc.&#xD;
&#xD;
         20. Cerebrovascular disease.&#xD;
&#xD;
         21. Cystic fibrosis.&#xD;
&#xD;
         22. Neurologic conditions, such as dementia.&#xD;
&#xD;
         23. Hereditary or acquired angioneurotic edema.&#xD;
&#xD;
         24. Urticaria in the last 12 months.&#xD;
&#xD;
         25. No spleen or functional asplenia.&#xD;
&#xD;
         26. Platelet disorder or other bleeding disorder that may cause injection&#xD;
             contraindication.&#xD;
&#xD;
         27. Chronic use (more than 14 continuous days) of any medications that may be associated&#xD;
             with impaired immune responsiveness within 3 months before administration of study&#xD;
             vaccine. (Including, but not limited to, systemic corticosteroids exceeding 10 mg/day&#xD;
             of prednisone equivalent, allergy injections, immunoglobulin, interferon,&#xD;
             immunomodulators. The use of low dose topical, ophthalmic, inhaled and intranasal&#xD;
             steroid preparations will be permitted.)&#xD;
&#xD;
         28. Prior administration of blood products in last 4 months.&#xD;
&#xD;
         29. Prior administration of other research medicines in last 1 month.&#xD;
&#xD;
         30. Received or plans to receive an attenuated vaccine within 1 month before or after each&#xD;
             study vaccination.&#xD;
&#xD;
         31. Received or plans to receive an inactivated vaccine within 14 days before or after&#xD;
             each study vaccination.&#xD;
&#xD;
         32. Current treatment with investigational agents for prophylaxis of COVID-19.&#xD;
&#xD;
         33. Have a household contact that has been diagnosed with COVID-19.&#xD;
&#xD;
         34. Current anti-tuberculosis prophylaxis or therapy.&#xD;
&#xD;
         35. Currently receiving treatment for cancer or history of cancer in the last five years&#xD;
             (except basal cell carcinoma of the skin and cervical carcinoma in situ).&#xD;
&#xD;
         36. According to the judgement of investigator, various medical, psychological, social or&#xD;
             other conditions that could affect the subjects ability to sign informed consent.&#xD;
&#xD;
         37. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lennie Sender</last_name>
    <phone>714-615-2350</phone>
    <email>Lennie.Sender@NantKwest.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Fridman</last_name>
      <phone>949-764-4430</phone>
      <email>Deborah.fridman@hoag.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

